CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 24 enrolled
Drug / intervention
Bi-hormonal closed loop pump +2 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02397265
NCT02397265N/ACompleted

Clinical Assessment of a Closed-loop System With Glucagon, Exercise and Mixed Meals

Imperial College London·interventional·Posted Mar 24, 2015·Updated Nov 1, 2019

In Brief

A clinical study evaluating Bi-hormonal closed loop pump, Standard opened loop pump, and 1 other intervention for Type 1 Diabetes. Completed, enrolled 24 participants across 1 site.

Detailed Summary

The diabetes technology group at Imperial College have developed a bio-inspired artificial pancreas (BiAP) system which uses a control algorithm based on a mathematical model of beta-cell physiology. The algorithm is implemented on a miniature silicon microchip within a portable handheld device, which interfaces the components of the artificial pancreas. Development of closed-loop insulin delivery devices to intensify control without hypoglycaemia has been extensively reviewed and have shown encouraging results . However, they have not yet proven to be robust when challenged with uncertainty and the external challenges (such as mixed meal contents, physical exercise, physiological stress and intercurrent illness) that people with Type 1 Diabetes Mellitus (T1DM) may be exposed to outside the clinical environment. The principal research objective is to assess the safety and efficacy of a closed-loop system for T1DM compared to standard insulin pump therapy (open-loop). The primary outcome from the studies will be % time spent with a glucose concentration in the target range (3.9-10.0mmol/l). This outcome incorporates safety as it ensures subjects do not have low or high glucose excursions and is the principal measure of efficacy for closed-loop insulin delivery systems in the scientific literature. Other measured outcomes will be % time spent in euglycaemia (3.9-7.8mmol/l), % time spent in hypoglycaemia (\<3.9mmol/l), % time spent in hyperglycaemia (\>10mmol/l), mean venous blood and sensor glucose, glycaemic variability as measured by standard metrics (Standard Deviation, Continuous Overlapping Net Glycaemic Action, Lability Index, J-Index, Glycaemic Risk Assessment Diabetes Equation, Mean Of Daily Differences, Mean Amplitude of Glucose Excursion, Average Daily Risk Range, M-VALUE, Mean Average Glucose), glycaemic risk as measured by Low Blood Glucose Index (LBGI) and High Blood Glucose Index (HBGI), closed-loop error grid analysis, glucose area under the curve. All measures have been previously published and validated. This clinical trial protocol assesses the artificial pancreas system in three separate sub-studies: 1. In a bi-hormonal (insulin and glucagon) configuration 2. During and after exercise with bi-hormonal closed loop, and standard insulin opened loop 3. During and after meals of mixed composition with bi-hormonal closed loop, and standard insulin opened loop

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 1 Diabetes
CountriesUnited Kingdom
Collaborators--

Timeline

N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedMar 24, 2015
Enrollment StartDec 3, 2014
Primary CompletionJul 22, 2015
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 11.3 years ago

Interventions

Bi-hormonal closed loop pumpdevice

Using a bio-inspired artificial pancreas consisting of a bi-hormonal closed loop pump

Standard opened loop pumpdevice

Using a standard opened loop pump

Insulin closed loopdevice

Using a closed loop